The Assessment of the Effect of Autophagy Inhibitors—Chloroquine and 3-Methyladenine on the Antitumor Activity of Trametinib Against Amelanotic Melanoma Cells
Cells · 2025
DOI: 10.3390/cells14070557 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cells, 2025. Verfasst von Dominika Stencel und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Chemistry, Faculty of Pharmaceutical Sciences in Sosnowiec, Medical University of Silesia in Katowice, 4 Jagiellońska St…. Hauptthemen laut MEDLINE: Pyridones, Autophagy, Pyrimidinones, Adenine. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medical University of Silesia in Katowice.
Abstract (Originalsprache)
Malignant melanoma, particularly amelanotic melanoma, contributes to a very serious problem in public health. One way to find new therapies is to learn about and understand the molecular pathways that regulate cancer growth and development. In the case of a tumor, the autophagy process can lead to the development or inhibition of cancer. This study aimed to assess the cytotoxicity of connection trametinib (MEK1 and MEK2 kinase inhibitor) with autophagy inhibitors—chloroquine (lysosomal clearance of autophagosomes inhibitor) and 3-methyladenine (phosphatidylinositol 3-kinases inhibitor), on two amelanotic melanoma cell lines (C32 and A-375). The results showed that combination therapy had better anti-proliferative effects than alone therapy in both cell lines. The C32 cell line was more sensitive to 3-methyladenine treatment (alone and in combinations), and the A375 line showed sensitivity to chloroquine and 3-methyladenine (alone and in combinations). The anti-proliferative effect was accompanied by dysregulation of the cell cycle, a decrease in the reduced thiols, the depolarization of the mitochondrial membrane and the level of p44/p42 MAPK. Both inhibitors have the ability to induce apoptosis. Differences in the level of LC3A/B and LC3B proteins between the chloroquine and the 3-methyladenine samples indicate that these drugs inhibit autophagy at different stages. The enhancement of the effect of trametinib by autophagy inhibitors suggests the possibility of combining drugs with anti-cancer potential with modulators of the autophagy process.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmaceutical Chemistry, Faculty of Pharmaceutical Sciences in Sosnowiec, Medical University of Silesia in Katowice, 4 Jagiellońska Str., 41-200 Sosnowiec, Poland.
ORCID-Profile: Dominika Stencel, Justyna Kowalska, Zuzanna Rzepka, Klaudia Banach, Dorota Wrześniok
Förderung
- Medical University of Silesia in Katowice
Zitieren
APA
Stencel, D., Kowalska, J., Rzepka, Z., Banach, K., Karkoszka-Stanowska, M., & Wrześniok, D. (2025). The Assessment of the Effect of Autophagy Inhibitors—Chloroquine and 3-Methyladenine on the Antitumor Activity of Trametinib Against Amelanotic Melanoma Cells. Cells. https://doi.org/10.3390/cells14070557
Vancouver
Stencel D, Kowalska J, Rzepka Z, Banach K, Karkoszka-Stanowska M, Wrześniok D. The Assessment of the Effect of Autophagy Inhibitors—Chloroquine and 3-Methyladenine on the Antitumor Activity of Trametinib Against Amelanotic Melanoma Cells. Cells. 2025. doi:10.3390/cells14070557
BibTeX
@article{Stencel2025,
author = {Stencel, Dominika and Kowalska, Justyna and Rzepka, Zuzanna and Banach, Klaudia and Karkoszka-Stanowska, Marta and Wrześniok, Dorota},
title = {The Assessment of the Effect of Autophagy Inhibitors—Chloroquine and 3-Methyladenine on the Antitumor Activity of Trametinib Against Amelanotic Melanoma Cells},
journal = {Cells},
year = {2025},
doi = {10.3390/cells14070557}
}
EUVIMED